OptimizeRx Statistics
Total Valuation
OptimizeRx has a market cap or net worth of $170.14 million. The enterprise value is $186.37 million.
Important Dates
The next confirmed earnings date is Monday, May 12, 2025, after market close.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
OptimizeRx has 18.49 million shares outstanding. The number of shares has increased by 6.82% in one year.
| Current Share Class | 18.49M |
| Shares Outstanding | 18.49M |
| Shares Change (YoY) | +6.82% |
| Shares Change (QoQ) | +0.52% |
| Owned by Insiders (%) | 14.46% |
| Owned by Institutions (%) | 57.35% |
| Float | 14.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 21.30 |
| PS Ratio | 1.83 |
| Forward PS | 1.70 |
| PB Ratio | 1.45 |
| P/TBV Ratio | 190.10 |
| P/FCF Ratio | 35.62 |
| P/OCF Ratio | 25.64 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 176.82, with an EV/FCF ratio of 39.01.
| EV / Earnings | n/a |
| EV / Sales | 1.97 |
| EV / EBITDA | 176.82 |
| EV / EBIT | n/a |
| EV / FCF | 39.01 |
Financial Position
The company has a current ratio of 2.82, with a Debt / Equity ratio of 0.28.
| Current Ratio | 2.82 |
| Quick Ratio | 2.69 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 25.15 |
| Debt / FCF | 6.87 |
| Interest Coverage | -0.56 |
Financial Efficiency
Return on equity (ROE) is -12.91% and return on invested capital (ROIC) is -1.34%.
| Return on Equity (ROE) | -12.91% |
| Return on Assets (ROA) | -1.20% |
| Return on Invested Capital (ROIC) | -1.34% |
| Return on Capital Employed (ROCE) | -2.21% |
| Revenue Per Employee | $731,512 |
| Profits Per Employee | -$119,457 |
| Employee Count | 129 |
| Asset Turnover | 0.55 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -704,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.89% in the last 52 weeks. The beta is 1.28, so OptimizeRx's price volatility has been higher than the market average.
| Beta (5Y) | 1.28 |
| 52-Week Price Change | -14.89% |
| 50-Day Moving Average | 8.05 |
| 200-Day Moving Average | 6.86 |
| Relative Strength Index (RSI) | 54.34 |
| Average Volume (20 Days) | 167,345 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OptimizeRx had revenue of $94.37 million and -$15.41 million in losses. Loss per share was -$0.84.
| Revenue | 94.37M |
| Gross Profit | 60.52M |
| Operating Income | -3.30M |
| Pretax Income | -25.32M |
| Net Income | -15.41M |
| EBITDA | 1.05M |
| EBIT | -3.30M |
| Loss Per Share | -$0.84 |
Full Income StatementBalance Sheet
The company has $16.57 million in cash and $32.80 million in debt, giving a net cash position of -$16.23 million or -$0.88 per share.
| Cash & Cash Equivalents | 16.57M |
| Total Debt | 32.80M |
| Net Cash | -16.23M |
| Net Cash Per Share | -$0.88 |
| Equity (Book Value) | 116.27M |
| Book Value Per Share | 6.29 |
| Working Capital | 33.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $6.64 million and capital expenditures -$107,000, giving a free cash flow of $4.78 million.
| Operating Cash Flow | 6.64M |
| Capital Expenditures | -107,000 |
| Free Cash Flow | 4.78M |
| FCF Per Share | $0.26 |
Full Cash Flow StatementMargins
Gross margin is 64.13%, with operating and profit margins of -3.50% and -16.33%.
| Gross Margin | 64.13% |
| Operating Margin | -3.50% |
| Pretax Margin | -17.08% |
| Profit Margin | -16.33% |
| EBITDA Margin | 1.12% |
| EBIT Margin | -3.50% |
| FCF Margin | 5.06% |
Dividends & Yields
OptimizeRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.82% |
| Shareholder Yield | -6.82% |
| Earnings Yield | -9.06% |
| FCF Yield | 2.81% |
Analyst Forecast
The average price target for OptimizeRx is $9.06, which is -1.52% lower than the current price. The consensus rating is "Buy".
| Price Target | $9.06 |
| Price Target Difference | -1.52% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on May 14, 2018. It was a reverse split with a ratio of 0.33333:1.
| Last Split Date | May 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 0.33333:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |